Invetech Delivers First Fully Automated Cell Therapy Units to Argos Therapeutics
11 November 2010
Invetech and Argos Therapeutics today announced the delivery of custom designed cell therapy automation units to Argos to facilitate the manufacturing of Argos’ personalized RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases at commercial scale.
Jeff Abbey, president and chief executive officer of Argos, said, "The Arcelis immunotherapy is the first and only fully automated process that lowers labor and production costs while benefiting from economies of scale. With virtually no risk of process inconsistency and contamination due to the use of robotics in a closed, airtight system, Arcelis addresses the manufacturing challenges of personalized immunotherapies, including meeting the needs of large patient populations in cancer and infectious diseases."
Further Press Information
Alan Morris, Phone: +613 9211 7815, Fax: +613 9211 7703. Media Inquiries.